Clinical Trials | December 18, 2025
Astellas & Pfizer report breakthrough Phase 3 results in muscle-invasive bladder cancer
The combination also outperformed chemotherapy on another important secondary endpoint
The combination also outperformed chemotherapy on another important secondary endpoint
Zyrifa is indicated for patients with bone metastases stemming from a wide range of solid tumors
Dr Reddy’s will pay Immutep US$ 20 million upfront and could deliver as much as US$ 349.5 million in regulatory and commercial milestones
The partnership also allows both companies to explore CR-001 and SKB105 as monotherapies and in combination
Under the proposed terms, Vaximm would secure a $20 million upfront payment, up to $815 million tied to clinical, regulatory, and commercial milestones
The oral, film-coated tablet is licensed for patients whose cancer has returned during or shortly after hormone therapy
The hospital has already onboarded 200+ experienced doctors and is expected to generate 5,000–7,000 jobs
Abbott is eyeing to become a global powerhouse in early cancer detection and precision oncology
Novartis is the only pharmaceutical company with a dedicated commercial RLT portfolio
Subscribe To Our Newsletter & Stay Updated
